Eli Lilly today announced plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park.
The facility will incorporate advanced manufacturing technologies to meet the needs of Lilly's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. Innovative capabilities will include dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion, which allows oral medicines to be effectively absorbed.
The new site will also be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist. The company expects to submit orforglipron to global regulatory agencies for obesity by the end of this year.
Lilly will bring 500 jobs to the South Holland province, including engineers, scientists, operations personnel and lab technicians, who will leverage state-of-the-art technology to produce life-changing medicines. In addition, an estimated 1,500 jobs will be created during construction, which is expected to begin next year. Lilly's investment is contingent upon the finalization of government permits and local approvals.
The company recently announced plans to expand an existing manufacturing site in Puerto Rico and to build sites in Texas and Virginia. Two more U.S. locations will be announced in the next few months.
